Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension.
Animals
Antihypertensive Agents
/ administration & dosage
Desoxycorticosterone Acetate
/ toxicity
Drug Therapy, Combination
Endothelin Receptor Antagonists
/ administration & dosage
Hypertension
/ chemically induced
Male
Pyrimidines
/ administration & dosage
Rats
Rats, Inbred SHR
Rats, Wistar
Renin-Angiotensin System
/ drug effects
Sulfonamides
/ administration & dosage
Journal
The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
24
09
2018
accepted:
27
12
2018
pubmed:
10
1
2019
medline:
2
11
2019
entrez:
10
1
2019
Statut:
ppublish
Résumé
The endothelin (ET) system has emerged as a novel target for hypertension treatment where a medical need persists despite availability of several pharmacological classes, including renin angiotensin system (RAS) blockers. ET receptor antagonism has demonstrated efficacy in preclinical models of hypertension, especially under low-renin conditions and in hypertensive patients. We investigated the pharmacology of aprocitentan (
Identifiants
pubmed: 30622171
pii: jpet.118.253864
doi: 10.1124/jpet.118.253864
doi:
Substances chimiques
Antihypertensive Agents
0
Endothelin Receptor Antagonists
0
Pyrimidines
0
Sulfonamides
0
Desoxycorticosterone Acetate
6E0A168OB8
aprocitentan
MZI81HV01P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
462-473Informations de copyright
Copyright © 2019 The Author(s).